The purpose of tumor staging is to guide treatment,and the treatment for a certain stage should be adjusted based on the changes in disease condition,in order to facilitate better control of tumor. Therefore,the treatment of liver cancer requires follow-up and re-staging to develop better treatment regimens for patients,especially the opportunity for cure. Surgical resection is not suitable for large hepatocellular carcinoma confined to the liver,and after embolization chemotherapy combined with radiotherapy for tumor regression and downstaging,some patients may undergo surgical resection,and the incurable tumor can thus be cured. For liver cancer patients with portal vein tumor thrombus,surgical resection can be performed after tumor thrombus is reduced by neoadjuvant radiotherapy,and the patients undergoing neoadjuvant radiotherapy have a significant increase in survival time than those not undergoing neoadjuvant radiotherapy. Large hepatocellular carcinoma can be downstaged to small hepatocellular carcinoma after multimodality therapy,and then stereotactic radiotherapy or radiofrequency ablation can help to achieve radical treatment. There is an increasing number of clinical reports of radiotherapy for liver cancer downstaging,with a gradual increase in evidence-based level,and thus it holds promise for clinical application.
[1] ZENG ZC,TANG ZY,YANG BH,et al. Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma[J]. Eur J Nucl Med,2002,29(12):1657-1668.
|
[2] ZENG ZC,TANG ZY,ZHOU J,et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma[J]. Cancer J,2004,10(5):307-316.
|
[3] KAMIYAMA T,NAKANISHI K,YOKOO H,et al. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma[J]. Int J Clin Oncol,2007,12(5):363-368.
|
[4] WEI X,JIANG Y,ZHANG X,et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus:A randomized,open-label,multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.
|
[5] KIM J,LEE I,KIM J,et al. Clinical features of hepatocellular carcinoma patients undergoing resection after concurrent chemoradiation therapy[J]. Int J Radiat Oncol Biol Phys,2012,84(Suppl 3):s336-s337.
|
[6] WIGG A,HON K,MOSEL L,et al. Down-staging of hepatocellular carcinoma via external-beam radiotherapy with subsequent liver transplantation:A case report[J]. Liver Transpl,2013,19(10):1119-1124.
|
[7] JEONG Y,SHIN MH,YOON SM,et al. Liver transplantation after transarterial chemoembolization and radiotherapy for hepatocellular carcinoma with vascular invasion[J]. J Gastrointest Surg,2017,21(2):275-283.
|
[8] CHOI JY,YU JI,PARK HC,et al. The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus[J].Liver Transpl,2017,23(4):545-551.
|
[9] KATZ AW,CHAWLA S,QU ZH,et al. Stereotactic hypofractionated radiation therapy as a bridge to transplantation for hepatocellular carcinoma:Clinical outcome and pathologic correlation[J]. Int J Radiat Oncol Biol Phys,2012,83(3):895-900.
|
[10] O’CONNOR JK,TROTTER J,DAVIS GL,et al. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation[J]. Liver Transpl,2012,18(8):949-954.
|
[11] SAPISOCHIN G,BARRY A,DOHERTY M,et al. Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma. An intention-totreat analysis[J]. J Hepatol,2017,67(1):92-99.
|
[12] BUSH DA,SMITH JC,SLATER JD,et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma:Results of an interim analysis[J]. Int J Radiat Oncol Biol Phys,2016,95(1):477-482.
|
[13] WONG TC,CHIANG CL,LEE AS,et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma:A propensity score matched analysis[J]. Surg Oncol,2019,28:228-235.
|
[14] Chinese Society of Liver Cancer,Chinese Medical Doctor Association. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus(2018)[J]. J Clin Hepatol,2019,35(4):737-743.(in Chinese)中国医师协会肝癌专业委员会.肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2018年版)[J].临床肝胆病杂志,2019,35(4):737-743.
|